> Detailanzeige

Zheludkova, Olga; Olkhova, Lyudmila; Kushel’, Yuri; Melikyan, Armen; Ryzhova, Marina; Shishkina, Lyudmila; Golanov, Andrey; Kislyakov, Alexey; Shultz, Evgeny; Borodina, Irina; Gorbatykh, Svetlana; Popov, Vladimir; Mushinskaya, Marina; Polushkina, Olga; Inyushkina, Еugenia; Yudina, Natalia; Privalova, Lyudmila; Minkina, Lyudmila; Zaichikov, Artem; Matsekha, Evgeny; Fisyun, Ivan; Sakun, Daniil; Dunaeva, Nadezhda; Avanesyan, Svetlana; [...]

MBCL-31. TREATMENT RESULTS AMONG 106 PATIENTS WITH MEDULLOBLASTOMA OF MOLECULAR SUBGROUP 3

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: MBCL-31. TREATMENT RESULTS AMONG 106 PATIENTS WITH MEDULLOBLASTOMA OF MOLECULAR SUBGROUP 3
  • Beteiligte: Zheludkova, Olga; Olkhova, Lyudmila; Kushel’, Yuri; Melikyan, Armen; Ryzhova, Marina; Shishkina, Lyudmila; Golanov, Andrey; Kislyakov, Alexey; Shultz, Evgeny; Borodina, Irina; Gorbatykh, Svetlana; Popov, Vladimir; Mushinskaya, Marina; Polushkina, Olga; Inyushkina, Еugenia; Yudina, Natalia; Privalova, Lyudmila; Minkina, Lyudmila; Zaichikov, Artem; Matsekha, Evgeny; Fisyun, Ivan; Sakun, Daniil; Dunaeva, Nadezhda; Avanesyan, Svetlana; [...]
  • Erschienen: Oxford University Press (OUP), 2020
  • Erschienen in: Neuro-Oncology
  • Sprache: Englisch
  • DOI: 10.1093/neuonc/noaa222.507
  • ISSN: 1522-8517; 1523-5866
  • Schlagwörter: Cancer Research ; Neurology (clinical) ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>To evaluate the treatment results among 106 patients of molecular subgroup 3 and to determine the factors affecting the prognosis.</jats:p> </jats:sec> <jats:sec> <jats:title>PATIENTS AND METHODS</jats:title> <jats:p>In all the patients, initial removal of the tumor was performed. All the patients got chemoradiotherapy according to the HIT protocol. There were 34girls and 72boys. Most patients were over 3 years:74 compared to 32 younger than 3. The majority of the patients had stage M+: 65; in 38 stage M0 was determined; in 3patients, stage was not specified, Mx.MYC amplification was found in 20 patients; MYCN amplification, in 4 patients. Classic medulloblastoma was predominant: 65, and 41 patients had anaplastic/large cell medulloblastoma.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>The five-year progression-free survival was 0.51±0.05, the five-year overall survival was 0.52±0.04.The median survival was 82months,and the median progression-free survival was 37 months. There were no significant variations of PFS depending on the sex and age. The treatment results depended on the histological subtype: for classic medulloblastoma, the five-year PFS was 0.57; for the anaplastic/largecell,0.38(р = 0.02030). The presence of metastases significantly affected the survival: PFS for stage M0 was 0.77; for stage М+,0.35(р = 0.00062). Patients with MYC amplification had a significantly worse survival compared to MYCN patients and those without MYC amplification: 0.1, 0.75, and 0.58, respectively (р = 0.00002). Three patients with MYC amplification are alive: two patients had MGMT methylation detected.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>The results of treatment among the patients with molecular subgroup 3 depended on the tumor subtype, presence of metastases, MYC amplification and MGMT methylation. In the absence of unfavorable factors, the survival was the same as in molecular subgroup 4.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang